JERUSALEM, Israel--(BUSINESS WIRE)--April 5, 2006--A new, higher dose of Copaxone® (glatiramer acetate injection) showed promising results in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). A 9-month, randomized, double-blind, parallel-group phase II study of 90 patients comparing a 40 mg dose of Copaxone® to the currently approved 20 mg dose showed a 38% greater reduction in mean cumulative number of gadolinium (Gd)-enhancing lesions as measured by magnetic resonance images (MRI) of the brain in patients taking the higher dose compared with those taking the 20 mg dose. In addition, patients taking Copaxone® 40 mg experienced a reduced mean on-trial relapse rate of 77% when compared to annual relapse rate prior to entry, as compared to 62% with Copaxone® 20 mg.
